Archives for March 2, 2009

← 2009

“Untrue data” from Ranbaxy plant news to Daiichi

By Gareth Macdonald

 Daiichi Sankyo, the Japanese drug firm that bought a controlling stake in India’s Ranbaxy last year, says it had no knowledge of FDA concerns that led to a block on ANDA reviews for drugs made at the latter’s Paonta Sahib facility.

Partnership aims for complete toxicology model

By Nick Taylor

Genstruct and Gene Logic are partnering to improve their service offerings, with the collaboration hoping to produce network models that fully capture the toxicity potential of any compound.

Elan cuts jobs, shelves biofacility

By Phil Taylor

Faced with a tougher operating environment, Irish drugmaker Elan has decided to slash staff numbers by 230 – or around 14 per cent of its total workforce – shelve the construction of a new biologics manufacturing facility and shutter fill-and-finish...

ChanTest buys GPCR specialist

By Phil Taylor

Contract research company ChanTest has acquired fellow US firm Applied Clinical Sciences, a specialist in the development of drugs that affect G-protein coupled receptors (GPCR), one of the most fertile areas of drug discovery.